Abstract | BACKGROUND: PATIENTS AND METHODS: One hundred and eighty women with stage I-III breast cancer who received PLD-based adjuvant chemotherapy at six different Institutions in Taiwan from February 2002 to March 2008 were included and followed-up until April 2015. Treatment efficacy was determined by disease-free survival (DFS) rate and safety was evaluated by adverse events. RESULTS: The 5- and 10-year DFS rates were 76.3 and 72.6%, respectively. Univariate analysis revealed that tumor size >5 cm (p=0.045; hazard ratio=3.31) and stage III (hazard ratio=3.54; p=0.019) were each associated with shorter DFS. Only stage III (hazard ratio=5.60; p=0.018) retained statistical significance with regard to DFS in the multivariate analysis. Grade 3/4 hematological toxicity was neutropenia (n=13; 7.2%). The women receiving PLD had low-grade 3 or 4 nausea/ vomiting, mucositis, and alopecia. Grade 3 hand-foot syndrome occurred in three patients (1.7%). CONCLUSION:
|
Authors | Yin-Che Lu, F U Ou-Yang, Chia-Ming Hsieh, King-Jen Chang, Dar-Ren Chen, Chi-Wen Tu, Hwei-Chung Wang, Ming-Feng Hou |
Journal | In vivo (Athens, Greece)
(In Vivo)
2016 Mar-Apr
Vol. 30
Issue 2
Pg. 159-63
ISSN: 1791-7549 [Electronic] Greece |
PMID | 26912829
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. |
Chemical References |
- Antibiotics, Antineoplastic
- liposomal doxorubicin
- Polyethylene Glycols
- Doxorubicin
|
Topics |
- Adult
- Aged
- Antibiotics, Antineoplastic
(administration & dosage, adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy, mortality, pathology, surgery)
- Chemotherapy, Adjuvant
- Combined Modality Therapy
- Doxorubicin
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Female
- Humans
- Middle Aged
- Neoplasm Staging
- Polyethylene Glycols
(administration & dosage, adverse effects, therapeutic use)
- Risk Factors
- Treatment Outcome
- Tumor Burden
|